Impotence, commonly used in modern clinical language to refer to erectile dysfunction (ED), is the persistent or recurrent inability to achieve and/or maintain an erection sufficient for satisfactory sexual performance. While the term “impotence” is older, it remains relevant as a patient-facing descriptor. ED is not a disease of “will” or “masculinity”; it reflects measurable dysfunction in vascular, neurologic, endocrine, and psychosocial systems that coordinate erection.
Erection is a neurovascular event driven by sexual stimulation and mediated by the parasympathetic nervous system. Sexual arousal leads to nitric oxide (NO) release within penile smooth muscle, increasing cyclic guanosine monophosphate (cGMP). This cascade relaxes cavernosal arteries and trabecular smooth muscle, allowing increased arterial inflow and trapping of blood within the corpora cavernosa via veno-occlusion. Any impairment along this pathway—reduced NO bioavailability, endothelial dysfunction, inadequate neural signaling, structural damage to penile tissues, or disturbed hormonal signaling—can result in ED.
Vascular disease is a leading organic contributor. Atherosclerosis, hypertension, diabetes mellitus, dyslipidemia, and smoking reduce endothelial function and arterial inflow, and they also accelerate microvascular injury. Because penile arteries are relatively small, ED can be an early marker of systemic vascular disease, sometimes preceding clinically overt coronary artery disease. Neurologic causes include spinal cord injury, multiple sclerosis, Parkinson’s disease, peripheral neuropathies (including diabetic neuropathy), and post-surgical or traumatic nerve damage. Endocrine disorders such as hypogonadism (low testosterone) can reduce libido and impair erection quality, while hyperprolactinemia and thyroid disorders may contribute indirectly through effects on sexual desire and metabolism. Pelvic surgery (e.g., radical prostatectomy), radiation therapy, and certain medications are additional common contributors.
Medication-related ED is frequent and often under-recognized. Antihypertensives (especially older agents like non-selective beta-blockers), antidepressants (notably selective serotonin reuptake inhibitors), antipsychotics, opioids, and 5-alpha reductase inhibitors can affect erections through vascular, endocrine, or central mechanisms. Psychogenic factors remain important: performance anxiety, depression, relationship discord, and stress-related sympathetic overactivity can inhibit parasympathetic arousal and disrupt attention to sexual cues. Notably, ED often has mixed etiology: even when an anxiety component exists, vascular risk may still be present.
Clinical evaluation begins with a targeted sexual and medical history. Key domains include onset (sudden vs gradual), duration, erection quality, nocturnal or morning erections, libido, orgasm quality, curvature or pain, and medication or substance use. Nocturnal penile tumescence testing and patient-reported patterns can help distinguish psychogenic from organic causes, though definitive separation is not always possible. Physical examination should assess blood pressure, cardiovascular signs, secondary sexual characteristics, and genital and testicular status. Laboratory testing commonly includes fasting glucose or HbA1c, lipid profile, morning total testosterone (often with repeat confirmation), and—if indicated—prolactin, thyroid-stimulating hormone, and other endocrine markers.
ED is categorized by severity and time course, guiding treatment selection. First-line therapy for many patients involves lifestyle and risk-factor modification: smoking cessation, improved glycemic control, weight reduction, exercise, blood pressure management, and limiting alcohol. These interventions improve endothelial function and can enhance responsiveness to pharmacotherapy.
Phosphodiesterase type 5 (PDE5) inhibitors are the cornerstone of oral ED treatment. By inhibiting PDE5, they potentiate the NO–cGMP pathway, improving cavernosal smooth muscle relaxation. Common agents include sildenafil, tadalafil, vardenafil, and avanafil. Contraindications are critical: PDE5 inhibitors should not be used with nitrates (due to profound hypotension risk) and require caution with certain antihypertensives and significant cardiovascular instability. Patients should be counseled about side effects (e.g., headache, flushing, dyspepsia, nasal congestion) and drug interactions.
If oral agents are ineffective or contraindicated, options include vacuum erection devices, intraurethral or intracavernosal therapies (such as alprostadil), and penile implants in carefully selected cases. Addressing underlying causes—improving hormonal balance in hypogonadism, optimizing diabetes care, treating depression or anxiety, and reevaluating medication regimens—often substantially improves outcomes.
Psychosexual counseling and evidence-based sex therapy can be beneficial, especially in performance anxiety or relationship-related ED. Cognitive-behavioral strategies help reduce catastrophic interpretations and improve sexual communication and arousal responsiveness. Importantly, effective management requires shared decision-making and sensitivity to stigma, since ED is strongly influenced by self-perception and expectations.
ED is common, treatable, and clinically meaningful beyond sexual health. Because it may signal cardiovascular and metabolic disease, evaluation provides an opportunity for prevention. Patients should seek medical care rather than relying solely on anecdote or embarrassment, and clinicians should approach the topic with trauma-informed communication and comprehensive risk assessment.
Source: [@MykhailoRohoza]
Mykhailo Rohoza: 🎭 Erich Maria Remarque made his strangest confession to Marlene Dietrich just a few hours after they met. He told her he was impotent. The movie star’s reaction was both unexpected and genuinely sincere. She laughed and said that was wonderful. They could simply talk, sleep. #breaking
— @MykhailoRohoza May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
